Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články
PubMed
29096853
DOI
10.1016/j.atherosclerosissup.2017.05.022
PII: S1567-5688(17)30064-8
Knihovny.cz E-zdroje
- Klíčová slova
- Kinetic targeting, Ovarian cancer, Pegylated doxorubicin, Pharmacokinetic, Plasma filtration,
- MeSH
- chemorezistence MeSH
- dospělí MeSH
- doxorubicin aplikace a dávkování škodlivé účinky analogy a deriváty krev farmakologie MeSH
- intravenózní infuze MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory vaječníků krev diagnóza farmakoterapie MeSH
- polyethylenglykoly aplikace a dávkování škodlivé účinky farmakologie MeSH
- příprava léků MeSH
- protinádorová antibiotika aplikace a dávkování škodlivé účinky krev farmakokinetika MeSH
- senioři MeSH
- tkáňová distribuce MeSH
- výměna plazmy metody MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- doxorubicin MeSH
- liposomal doxorubicin MeSH Prohlížeč
- polyethylenglykoly MeSH
- protinádorová antibiotika MeSH
INTRODUCTION: Nanoparticle-based drug delivery systems can overcome the dose-limited toxicity of cytostatics. Pegylated doxorubicin-containing liposomes (PLD) are able to reduce cardiotoxicity. PLD quickly (in 2 days) attains therapeutic concentration in tumorous tissue (kinetic targeting), while its distribution in normal tissue, which is a cause of mucocutaneous toxicity (MCT), is delayed. We examined PLD extracorporeal removal effectivity, using plasma filtration (PF) to determine whether the drug could be withheld prior to its organ distribution responsible for MCT toxicity. METHODS: Nine patients suffering from platinum-resistant ovarian cancer were treated with a infusion of 50 mg/m2 of PLD/cycle - for four cycles q4w. Over 44 (46)-47 (49) hours postinfusion, the patients (14 cycles in total) underwent PF using the cascade method. Doxorubicin blood concentration was monitored by the HPLC method during 116 h. Individual pharmacokinetic parameters of doxorubicin were estimated. RESULTS: Over 44 (46)-47 (49) hours postinfusion, a single one-volume plasma filtration removed 35 (22-45) % of the remaining doxorubicin amount in the body. Symptoms of MCT - PPE-like syndrome (grade 3) appeared in one patient. Only one adverse reaction (1/14-7%) - short-term malaise and nausea - was reported as being related to PF. CONCLUSION: PF does remove a clinically important amount of doxorubicin in a kinetic targeting approach, which can be a useful tool for the increased efficacy and tolerability of therapy with PLD. There were no serious signs of drug toxicity and/or PF-related adverse events.
Citace poskytuje Crossref.org
